



RESEARCH

Open Access

Overexpression of regenerating gene Ia appears to reflect aberration of crypt cell compartmentalization in sessile serrated adenoma/polyps of the colon

Kentaro Okamoto^{1,2†}, Takahiro Fujimori^{1†}, Takeshi Yamaguchi^{1,2}, Kazuhito Ichikawa¹, Shigeki Tomita¹, Tamotsu Sugai³, Johji Imura⁴, Yasuo Ohkura⁵, Takashi Yao⁶, Shigehiko Fujii⁷, Toshihiro Kusaka⁷, Akira Sekikawa⁸, Hirokazu Fukui⁹, Tsutomu Chiba¹⁰, Hiroyuki Kato² and Hiroyuki Mitomi^{1*}

Abstract

Background: Colorectal sessile serrated adenoma/polyps (SSA/Ps) are characterized by asymmetrical distribution of Ki67-positive cells, which varies among crypts and involves the crypt length to a variable extent; the pattern has been designated as aberration of crypt cell compartmentalization. The *regenerating gene* (*REG*) Ia is a cell growth and/or anti-apoptotic factor and its overexpression might be associated with aberration of crypt cell compartmentalization in SSA/Ps. We investigated REG Ia expression in SSA/Ps in comparison to hyperplastic polyps (HPs).

Methods: A total of 64 cases of serrated polyps (≥ 10 mm in size), including 53 SSA/Ps and 11 HPs, were included in the present study. Immunostaining was performed using a labeled streptavidin-biotin method. REG Ia expression was classified as follows: (i) expression of endocrine cells: grade 0 (a few positive cells) to 3 (marked increase in positive cells); (ii) expression of goblet cells: grade 0 (negative) to 2 (positive for crypts and surface epithelial cells); (iii) staining intensity of goblet cells: grade 0 (negative) to 2 (strong); (iv) staining intensity of crypt (absorptive) cell membranes: grade 0 (negative) to 2 (strong). The presence of aberration of crypt cell compartmentalization was assessed using Ki67 immunostaining.

Results: With regard to the REG Ia expression of endocrine cells, 8 out of 11 HPs (73%) were grade 0, whereas 51 of 53 SSA/Ps (96%) were grade 1 or higher ($p < 0.001$). With regard to the distribution of REG Ia-immunoreactive goblet cells, 10 of 11 HPs (91%) were grade 1, whereas 50 of 53 SSA/Ps (94%) were grade 2 ($p < 0.001$). A similar trend was found in the staining intensity of goblet cells or crypt cell membranes ($p = 0.011$). Aberration of crypt cell compartmentalization was more frequently identified in SSA/Ps (72%) than in HPs (18%; $p = 0.002$). A significant association was observed between REG Ia overexpression and the aberration of crypt cell compartmentalization in serrated polyps ($p = 0.037$).

Conclusions: REG Ia overexpression is a characteristic of SSA/Ps, which appears to reflect aberration of crypt cell compartmentalization.

Virtual slides: The virtual slide(s) for this article can be found here: <http://www.diagnosticpathology.diagnomx.eu/vs/7240956081100040>

Keywords: Colon, Crypt cell compartmentalization, Hyperplastic polyp, REG Ia, Sessile serrated adenoma/polyp

* Correspondence: hmitomi@dokkyomed.ac.jp

†Equal contributors

¹Department of Surgical and Molecular Pathology, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimotsuga, Tochigi 321-0293, Japan

Full list of author information is available at the end of the article

Background

In 1996, Torlakovic and Snover were the first to describe sessile-type serrated adenoma of the colon in an analysis of serrated adenomatous polyposis with the development of adenocarcinoma [1]. In 2003, Torlakovic et al. [2] refined the criteria and proposed a subclassification of colorectal serrated polyps into hyperplastic polyps (HPs), traditional serrated adenomas, and sessile serrated adenomas. The last category of serrated polyps is now designated as sessile serrated adenomas/polyps (SSA/Ps) in the fourth edition of the WHO Classification of Tumors of the Digestive System [3]. Although SSA/Ps and large HPs (≥ 10 mm in diameter), the latter was introduced by Warner et al. in 1994 [4], were synonymously used at times [5], SSA/Ps were histologically separated from large HPs [6,7]. SSA/Ps were characterized by irregular and asymmetrical distribution of Ki67-positive cells, which frequently varied among crypts and involved the crypt length to a variable extent; the pattern was designated as “aberration of crypt cell compartmentalization” [8]. This is consistent with the results of computer-assisted cytometric analysis of Ki67 immunoreactivity in SSA/Ps [6]. However, aberration of crypt cell compartmentalization was not a characteristic of large HPs as well as conventional (small) HPs [6,7].

The regenerating gene (REG) I α protein, the human homologue of the rat REG protein, was originally isolated from regenerating pancreatic islets [9], which were immunohistochemically positive for acinar, but not from islet cells of the pancreas [10]. REG I α protein has been found to be expressed in normal colorectal mucosa and colorectal tumors [11]. REG I α is also involved in the ulcerative colitis-neoplasia sequence [12,13]. Previous experimental studies have shown that REG I α promotes cell growth and/or anti-apoptosis of cancer cells [12,14].

A link between REG I α and β -catenin has been demonstrated in a study of liver cancer, in which β -catenin mutations induced REG I α expression in liver cancer cells [15]. In this context, REG I α expression together with aberrant β -catenin expression was associated with high Ki67 immunoreactivity in salivary gland tumors [16]. Recent studies have detected aberrant nuclear accumulation of β -catenin in SSA/Ps [17,18]. Wnt stimulation has been shown to lead to the inactivation of APC and the activation of β -catenin, resulting in nuclear accumulation of β -catenin, which subsequently complexes with the T-cell factor/lymphoid enhancer factor to activate target gene transcription resulting in cell proliferation [19]. These findings suggest that activation of Wnt/ β -catenin signaling is associated with aberration of crypt cell compartmentalization in SSA/Ps.

The aim of this study was to investigate the expression of REG I α in a subset of SSA/Ps and HPs and to discuss

its expression in relation to nuclear β -catenin expression and aberration of crypt cell compartmentalization.

Methods

Tissue samples and histological examination

Samples of 154 cases of serrated polyps (≥ 10 mm in size) were obtained from the Dokkyo Medical University Hospital and its affiliated institutions between 2003 and 2010. The diagnosis of SSA/P was made when a serrated lesion had two or more of the following three findings: irregularly branching crypts ($>10\%$ of the lesion), horizontally arranged basal crypts (inverted T- and/or L-shaped crypts) ($>10\%$ of the lesion), and crypt dilatation ($>10\%$ of the lesion), according to a previous report [6]. Serrated polyps with only one of the three findings were designated as intermediate type, and this type was included in HPs. Criteria for HP included narrow straight crypts with a normal distribution of the proliferative zone at the base of the crypts with uniform maturation and serration toward the surface [3]. Cases of mixed serrated polyps and conventional adenoma or traditional serrated adenoma were excluded. Some of the serrated polyps were excluded because of poor orientation of the specimens. Finally, a total of 64 cases of serrated polyps, including 53 SSA/Ps and 11 HPs (histologically renamed large HPs), were included in the present study. Clinicopathological characteristics of the serrated polyps studied are summarized in Table 1.

The ethics committee of the Dokkyo Medical University School of Medicine approved all protocols, and informed consent for tissue procurement was obtained from all patients. This work was conducted in a blinded manner using a linkable anonymizing method. Samples used in

Table 1 Clinicopathological characteristics of colorectal serrated polyps studied

	SSA/P (n = 53)	HP (n = 11)
Gender		
Male	28	6
Female	25	5
Age (yrs) [*]	55.4 (35–77)	59.3 (38–69)
Location		
Cecum	13	1
Ascending colon	16	3
Transverse colon	17	3
Descending colon	3	0
Sigmoid colon	4	3
Rectum	0	1
Tumor size (mm) [*]	13.2 (10–30)	10.6 (10–15)

^{*}Age and tumor size are represented as mean (range).

SSA/P: sessile serrated adenoma/polyp; HP: hyperplastic polyp.

this study were materials obtained for diagnosis or treatment, but not for research purposes. Participation in the present study did not increase the medical disadvantage or risk for patients.

Immunohistochemistry

Immunohistochemical staining for REG I α and Ki67 was performed with an LSAB-2 kit (Dako, Glostrup, Denmark) as described previously [13,20]. In brief, 4- μ m sections were placed on slides, deparaffinized, rehydrated, and then pretreated with 0.3% H₂O₂ in methanol for 20 min at room temperature to quench endogenous peroxidase activity. The slides were then placed in 0.01 ml/L citrate buffer (pH 6.0) and treated by microwave heating (400 W, 95°C; MI-77; Azumaya, Tokyo, Japan) to facilitate antigen retrieval.

The sections were first incubated with 1% bovine serum albumin in phosphate-buffered saline (PBS; pH 7.2) for 30 min and then with an anti-REG I α antibody (the source of the antibody is described in reference [10]; dilution 1:2,000) and anti-Ki67 antibody (DAKO; dilution 1:50) for 1 h. Thereafter, the sections were incubated with a biotinylated secondary antibody for 15 min, washed with PBS, and treated with peroxidase-conjugated streptavidin for 20 min. Finally, the sections were incubated in 3, 3'-diaminobenzidine tetrahydrochloride (Liquid DAB + Substrate Chromogen System; Dako, USA) with 0.05% H₂O₂ for 3 min and then counterstained with Mayer's hematoxylin.

Evaluation of immunohistochemical staining

In normal colon, REG I α expression is found in goblet cells and endocrine cells [13]. Furthermore, by using immunohistochemistry for chromogranin A, REG I α has been confirmed to be present exclusively in endocrine cells [21]. REG I α positive endocrine cells are pyramidally shaped and closed with a broad base that directly abuts the basement membrane. We therefore classified the expression of REG I α in a semiquantitative method according to the following scheme: (i) expression of endocrine cells: grade 0, a few (<1% of crypt cells) positive cells at the bottom of the crypt; grade 1, mild increase (1-5% of crypt cells) in the expression at the bottom of the crypt; grade 2, moderate increase (6-10% of crypt cells) in the expression at the bottom of the crypt and/or slight increase in the expression extending upward to surface epithelial cells; grade 3, marked increase (>10% of crypt cells) in the expression in crypt and surface epithelial cells; (ii) expression of goblet cells: grade 0, negative; grade 1, expression in crypt cells, but not in surface epithelial cells (\leq 50% of crypt cells); grade 2, expression in crypt and surface epithelial cells (>50% of crypt cells); (iii) staining intensity of goblet cells: grade 0, negative staining in goblet cells; grade 1, weak expression; grade 2, strong expression;

(iv) staining intensity of crypt (absorptive) cell membranes: grade 0, negative expression in any epithelial cell membrane; grade 1, weak membranous expression; grade 2, strong membranous expression. Immunostaining was evaluated in most representative areas showing highest intensity. Representative microphotographs of REG I α expression are illustrated in Figure 1.

We assessed the presence of aberration of crypt cell compartmentalization using Ki67 immunostaining and applied the criteria for aberration of crypt cell compartmentalization as described by Torlakovic et al. [8] as follows: an irregular distribution of Ki67-immunoreactive cells, which frequently varied among crypts, involved the crypt length to a variable extent, and was asymmetric in each individual crypt. Aberration of crypt cell compartmentalization was considered to be present when this feature existed in more than 10% of the crypt.

Every slide was examined simultaneously by four authors (KO, TY, HM, and TF) using a multi-head microscope, without prior knowledge of the clinicopathological data. In case of disagreement in the assessment of REG I α expression and the presence of aberration of crypt cell compartmentalization, the slide was re-examined and consensus was reached on further review.

Statistical analysis

Categorical analysis of variables was performed using either the chi-squared test (with Yates' correction) or Fisher's exact test, as appropriate. Continuous data were compared with the Mann-Whitney *U*-test. A *p* value of <0.05 was considered statistically significant. All statistical analyses were carried out using the R software (version 2.15.0).

Results

With regard to the REG I α expression of endocrine cells, 8 out of 11 HPs (73%) were grade 0 and 51 of 53 SSA/Ps (96%) were grades 1 to 3 (*p* <0.001). With regard to REG I α expression of goblet cells, 10 of 11 HPs (91%) were grade 1 and 50 of 53 SSA/Ps (94%) were grade 2 (*p* <0.001); a similar trend was found in the REG I α staining intensity of goblet cells (*p* <0.001). None of the HP cases showed crypt cell membrane expression of REG I α , but 26 of 53 SSA/Ps (49%) were positive for membranous expression (*p* =0.011; Table 2). The sum of the grading scores for the four items described above ranged from 2 - 9 (median, 6) in SSA/Ps and 2 - 4 (median, 3) in HPs; the values were significantly higher in SSA/Ps than in HPs (*p* <0.001). The expression patterns of REG I α in representative cases of SSA/Ps and HPs are illustrated in Figure 2. In a case of HP, diagnosed as inverted HP by serial sections, REG I α expression of goblet cells was grade 2 (Figure 3).

Aberration of crypt cell compartmentalization was more frequently identified in SSA/Ps (38 of 53 [72%]) than in




Figure 1 Immunohistochemical assessment (grading) of REG Ia expression.

Table 2 Immunoreactivity of REG Ia in SSA/Ps and HPs

REG Ia expression	SSA/P (n = 53)	HP (n = 11)	p value
Distribution of endocrine cells			
Grade 0	2	8	<0.001
Grade 1	30	1	
Grade 2	17	2	
Grade 3	4	0	
Distribution of goblet cells			
Grade 0	0	0	<0.001
Grade 1	3	10	
Grade 2	50	1	
Staining intensity of goblet cells			
Grade 0	0	0	<0.001
Grade 1	5	7	
Grade 2	48	4	
Staining intensity of crypt cell membrane			
Grade 0	27	11	0.011
Grade 1	19	0	
Grade 2	7	0	

SSA/P: sessile serrated adenoma/polyp; HP: hyperplastic polyp.

HPs (2 of 11 [18%]; $p = 0.002$). Of note, inverted HPs demonstrated aberration of crypt cell compartmentalization. In addition, we examined the association of REG Ia expression with aberration of crypt cell compartmentalization. In a combined analysis of SSA/Ps and HPs, high REG Ia expressors (sum of the grading score ≥ 5) were more frequent in serrated polyps with aberration of crypt cell compartmentalization (37 out of 40 [93%]) than in those without (14 out of 24 [58%]; $p = 0.037$).

We performed an ancillary immunohistochemical study of β -catenin (monoclonal antibody, Transduction Laboratories, Lexington, KY; dilution 1:2,000) in a case of SSA/P (Figure 4). In this case, nuclear and cytoplasmic expression of β -catenin was evident at the bottom of the crypt, similar to REG Ia.

Discussion

This is the first report to analyze REG Ia expression and crypt cell compartmentalization in serrated polyps. We show that REG Ia overexpression is a characteristic of SSA/Ps, as compared to (large) HPs. In analyses of ulcerative colitis-associated neoplasia, the expression of REG Ia gradually increased from regenerative mucosa through low-grade dysplasia to high-grade dysplasia; in this sequence, the distribution of proliferative cells increased similar to the REG Ia-positive region [12,13]. In addition, REG Ia-positive pleomorphic adenoma of the salivary gland demonstrated a significantly higher




Figure 2 Histology and immunohistochemistry for REG 1a and Ki67 of SSA/P and HP. (A) SSA/P showing irregularly branching crypts, horizontally arranged basal crypts, and crypt dilatation (hematoxylin & eosin); (B) REG 1a is mainly expressed in goblet cells in the entire crypt and surface epithelium in SSA/P (immunoperoxidase); (C) Ki67-immunoreactive cells in SSA/P are either increased or decreased or both, with irregular distribution; (D) HP represents narrow-shaped crypts without luminal serration in the basal part (hematoxylin & eosin); (E) REG 1a is weakly and sparsely expressed in goblet cells in HP (immunoperoxidase); (F) Ki67-immunoreactive cells are distributed regularly in the basal part of crypts in HP.




Figure 3 A case of inverted HP in the ascending colon. (A) Epithelial misplacement into the submucosa (arrows); (B) micropapillary projection at the surface area; (C) diffuse positivity for REG 1a in misplaced glands of the submucosa as well as in all glands of the mucosa; (D) REG 1a positivity representing goblet cells in the surface epithelium.




Figure 4 Expressions of REG I α and β -catenin in serial sections of a case of SSA/P. (A) Diffuse REG I α expression observed in the whole crypt cell population and surface epithelial cells; (B) strong cytoplasmic REG I α staining mainly in cells at the bottom of the crypt (magnifying view of 'box' in figure A); (C) β -catenin is expressed mainly in the cell membrane, except at the bottom of the crypt; (D) note expression of nuclear and cytoplasmic β -catenin at the bottom of the crypt, similar to REG I α (magnifying view of 'box' in figure C).

Ki67 labeling score than those negative for REG I α [16]. In previous reports, SSA/Ps demonstrated high proliferative activity with asymmetric localization of proliferative cells [6-8]. This observation is in line with our results that aberration of crypt cell compartmentalization was more frequently identified in SSA/Ps (72%) than in HPs (18%). We also found a significant association between REG I α overexpression and aberration of crypt cell compartmentalization in serrated polyps. In normal colonic crypts, endocrine cells and Paneth cells exist, in general, in proliferative and intermediate regions, and goblet cells are present only in the intermediate region [19]; however, in SSA/Ps, numerous goblet cells are identified at the base of the crypts (proliferative region) as well as in the intermediate region [2]. In SSA/Ps, there are abnormalities in the location of the various compartments (previously referred to as abnormal proliferation or dysmaturation [2]), a feature that Torlakovic et al. designated as the aberration of crypt compartmentalization [8].

Interestingly, we found that REG I α -expressing endocrine cells are increased in SSA/Ps. To our knowledge, endocrine cell hyperplasia has not been previously described in the context of SSA/Ps. In microvesicular-type HP, the number and/or size of endocrine cells are increased and they are mainly found in the intermediate region of the crypts [2]. Recently, Naert et al. reported a case of large cell neuroendocrine carcinoma arising in an SSA [22]. Corresponding to this case and our findings, REG I α is thought to be associated with endocrine cell hyperplasia and the development of neuroendocrine

tumors in SSA/Ps. Mutations in *REG I α* were identified in patients with carcinoid tumors [23], suggesting a link between its gain-of-function mutation and endocrine cell hyperplasia.

In our ancillary study, REG I α positivity was related to aberrant (non-membranous type) β -catenin expression in SSA/Ps. In conjunction with this finding, aberrant β -catenin expression was related to REG I α positivity in pleomorphic adenoma [16]. A link between REG I α and β -catenin has been demonstrated in a study of liver cancer, in which β -catenin mutations induced REG I α expression in liver cancer cells [15,16]. Therefore, REG I α may be a possible downstream target of the Wnt/ β -catenin signaling pathway. Wu et al. found aberrant nuclear labeling for β -catenin in 9 of 22 cases of SSA/Ps (41%). In a recent study, widespread or focal nuclear accumulation of β -catenin (using an N-terminus antibody) was also identified in 14 of 35 right-sided SSA/Ps (40%). Consequently, REG I α overexpression may contribute to the early activation of the Wnt/ β -catenin signaling pathway in SSA/Ps.

In the present study, we found one case of inverted HP displaying REG I α overexpression in the ascending colon with a maximum diameter of 15 mm. This is the only case of HP with REG I α overexpression similar to SSA/Ps. Inverted HPs as first described by Sobin et al. are an unusual morphological variant of HPs that show epithelial misplacement into the submucosa [24]. Inverted HPs are located in the rectum or sigmoid colon; their mean size is 5 mm [25]. To date, a small number of cases of inverted HP associated with adenoma and adenocarcinoma have

been reported [26-28]. An association of SSA/Ps with inverted HPs in addition to their ability of malignant progression remains unknown and an area of research and controversy.

Conclusions

This is the first report to demonstrate a correlation between SSA/P and REG I α expression. REG I α overexpression is a characteristic of SSA/Ps, which might be associated with aberration of crypt cell compartmentalization.

Abbreviations

SSA/P: Sessile serrated adenoma/polyp; HP: Hyperplastic polyp.

Competing interests

No financial and non-financial competing interests to declare in relation to this manuscript.

Authors' contributions

Study concept and design: TF and KO; immunohistochemical analysis: TY, KI ST and JI; acquisition of data: SF, TK, AS and HF; analysis of interpretation of data: HM and KO; drafting of the manuscript: KO, TH and HM; critical revision of the manuscript for intellectual content: TS, YO, TY and TC; study supervision: HK and TF. All authors read and approved the final manuscript.

Acknowledgments

We are grateful to Dr. Hiroshi Okamoto in Tohoku University Graduate School of Medicine, Sendai, Japan, for providing anti-REG I α antibody. The authors thank Dr. Yasushi Sano (Endoscopy Division, Gastrointestinal Center, Sano Hospital, Kobe, Japan), Dr. Akihiko Ohta (Ohta clinic, Tokyo, Japan), Dr. Takahiro Fujii (Takahiro Fujii Clinic, Tokyo, Japan), Dr. Yasushi Oda (Oda GI Clinic, Kumamoto, Japan) and Dr. Hideyo Goto (Hattori GI Endoscopy and Oncology Clinic, Kumamoto, Japan) for kindly supplying the clinical data. The authors would also like to thank Chiaki Matsuyama, Ayako Shimizu, Takako Ono, Midori Katayama, Sizuka Kidate and Atsuko Kikuchi (Department of Surgical and Molecular Pathology, Dokkyo Medical University School of Medicine, Mibu, Japan) for their excellent technical assistance. This work was supported in part by a Grant-in-Aid from the Japan Society for the Promotion of Science (#24590429 to Hiroyuki Mitomi and #23590410 to Takahiro Fujimori).

Author details

¹Department of Surgical and Molecular Pathology, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimotsuga, Tochigi 321-0293, Japan. ²First Department of Surgery, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimotsuga, Tochigi 321-0293, Japan. ³Division of Molecular Diagnostic Pathology, Department of Pathology, School of Medicine, Iwate Medical University, 19-1 Uchimarui, Morioka, Iwate 020-8505, Japan. ⁴Department of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama City, Toyama 930-0194, Japan. ⁵Department of Pathology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan. ⁶Department of Human Pathology, Juntendo University School of Medicine, 3-1-3 Hongo, Bunkyo-ku, Tokyo 113-8431, Japan. ⁷Department of Gastroenterology, Kyoto Katsura Hospital, 17 Yamada Hira, Nishikyoku, Kyoto 615-8256, Japan. ⁸Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, 5-30 Fudegasaki, Tennoji-ku, Osaka 543-8555, Japan. ⁹Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa, Nishinomiya, Hyogo 663-8501, Japan. ¹⁰Department of Gastroenterology and Hepatology, Kyoto, University Graduate School of Medicine, Yoshida-Konoe, Sakyo-ku, Kyoto 606-8501, Japan.

Received: 7 October 2013 Accepted: 29 October 2013

Published: 13 November 2013

References

1. Torlakovic E, Snover DC: **Serrated adenomatous polyposis in humans.** *Gastroenterology* 1996, **110**:748-755.
2. Torlakovic E, Skovlund E, Snover DC, Torlakovic G, Nesland JM: **Morphologic reappraisal of serrated colorectal polyps.** *Am J Surg Pathol* 2003, **27**:65-81.
3. Snover DC, Ahnen DJ, Burt RW, Odze RD: **Tumours of Digestive System.** In *WHO Classification of tumours, Pathology and genetics.* 4th edition. Edited by Bozman FT, Carneiro F, Hruban RH, Theise N. Lyon: International Agency for Research on Cancer; 2010:160-165.
4. Warner AS, Glick ME, Fogt F: **Multiple large hyperplastic polyps of the colon coincident with adenocarcinoma.** *Am J Gastroenterol* 1994, **89**:123-125.
5. Jass JR: **Serrated adenoma of the colorectum and the DNA-methylator phenotype.** *Nat Clin Oncol* 2005, **2**:398-405.
6. Fujimori Y, Fujimori T, Imura J, Sugai T, Yao T, Wada R, Ajioka Y, Ohkura Y: **An assessment of the diagnostic criteria for sessile serrated adenoma/polyps: SSA/Ps using image processing software analysis for Ki67 immunohistochemistry.** *Diagn Pathol* 2012, **7**:59.
7. Shida Y, Ichikawa K, Fujimori T, Fujimori Y, Tomita S, Fujii T, Sano Y, Oda Y, Goto H, Ohta A, Tanaka S, Sugai T, Yao T, Ohkura Y, Imura J, Kato H: **Differentiation between sessile serrated adenoma/polyp and non-sessile serrated adenoma/polyp in large hyperplastic polyp: A Japanese collaborative study.** *Mol Clin Oncol* 2013, **1**:53-58.
8. Torlakovic EE, Gomez JD, Driman DK, Parfitt JR, Wang C, Benerjee T, Snover DC: **Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA).** *Am J Surg Pathol* 2008, **32**:21-29.
9. Terazono K, Yamamoto H, Takasawa S, Shiga K, Yonemura Y, Tochino Y, Okamoto H: **A novel gene activated in regenerating islets.** *J Biol Chem* 1988, **263**:2111-2114.
10. Kimura N, Yonekura H, Okamoto H, Nagura H: **Expression of human regenerating gene mRNA and its product in normal and neoplastic human pancreas.** *Cancer* 1992, **70**:1857-1863.
11. Watanabe T, Yonekura H, Terazono K, Yamamoto H, Okamoto H: **Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. The reg protein, pancreatic stone protein, and pancreatic thread protein are one and the same product of the gene.** *J Biol Chem* 1990, **265**:7432-7439.
12. Sekikawa A, Fukui H, Fujii S, Nanakin A, Kanda N, Uenoyama Y, Sawabu T, Hisatsune H, Kusaka T, Ueno S, Nakase H, Seno H, Fujimori T, Chiba T: **Possible role of REG I α protein in ulcerative colitis and colitic cancer.** *Gut* 2005, **54**:1437-1444.
13. Tanaka H, Fukui H, Fujii S, Sekikawa A, Yamagishi H, Ichikawa K, Tomita S, Imura J, Yasuda Y, Chiba T, Fujimori T: **Immunohistochemical analysis of REG I α expression in ulcerative colitis-associated neoplastic lesions.** *Digestion* 2011, **83**:204-209.
14. Sekikawa A, Fukui H, Fujii S, Takeda J, Nanakin A, Hisatsune H, Seno H, Takasawa S, Okamoto H, Fujimori T, Chiba T: **REG I α protein may function as a trophic and/or anti-apoptotic factor in the development of gastric cancer.** *Gastroenterology* 2005, **128**:642-653.
15. Cavad C, Terris B, Grimber G, Christa L, Audard V, Radenen-Bussiere B, Simon MT, Renard CA, Buendia MA, Perret C: **Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with β -catenin mutations.** *Oncogene* 2006, **25**:599-608.
16. Hakata Y, Fukui H, Sekikawa A, Yamagishi H, Ichikawa K, Tomita S, Imura J, Kawamata H, Imai Y, Fujimori T: **Expression of β -catenin and REG I α in relation to cell proliferative ability in salivary gland tumors.** *Exp Ther Med* 2010, **1**:437-443.
17. Wu JM, Montgomery EA, Iacobuzio-Donahue CA: **Frequent β -catenin nuclear labeling in sessile serrated polyps of the colorectum with neoplastic potential.** *Am J Clin Pathol* 2008, **129**:416-423.
18. Li L, Fu X, Zhang W, Xiao L, Qiu Y, Peng Y, Shi L, Chen X, Zhou X, Deng M: **Wnt signaling pathway is activated in right colon serrated polyps correlating to specific molecular form of β -catenin.** *Hum Pathol* 2013, **44**:1079-1088.
19. Pinto D, Clevers H: **Wnt control of stem cells and differentiation in the intestinal epithelium.** *Exp Cell Res* 2005, **306**:357-363.
20. Fukui H, Fujii S, Takeda J, Kayahara T, Sekikawa A, Nanakin A, Suzuki K, Hisatsune H, Seno H, Sawada M, Fujimori T, Chiba T: **Expression of Reg I α protein in human gastric cancers.** *Digestion* 2004, **69**:177-184.
21. Asahara M, Mushiaki S, Shimada S, Fukui H, Kinoshita Y, Kawanami C, Watanabe T, Tanaka S, Ichikawa A, Uchiyama Y, Narushima Y, Takasawa S,

- Okamoto H, Tohyama M, Chiba T: *Reg* gene expression is increased in rat gastric enterochromaffin-like cells following water immersion stress. *Gastroenterology* 1996, **111**:45–55.
22. Naert K, Dupre MP: Large cell neuroendocrine carcinoma arising in a sessile serrated adenoma: a novel observation. *Hum Pathol* 2012, **43**:757–760.
 23. Higham AD, Bishop LA, Dimaline R, Blackmore CG, Dobbins AC, Varro A, Thompson DG, Dockray GJ: Mutations of *Regla* are associated with enterochromaffin-like cell tumor development in patients with hypergastrinemia. *Gastroenterology* 1999, **116**:1310–1318.
 24. Sobin LH: Inverted hyperplastic polyps of the colon. *Am J Surg Pathol* 1985, **9**:265–272.
 25. Yantiss RK, Goldman H, Odze RD: Hyperplastic polyp with epithelial misplacement (inverted hyperplastic polyp): a clinicopathologic and immunohistochemical study of 19 cases. *Mod Pathol* 2001, **14**:869–875.
 26. Kuribayashi K, Ishii T, Ishidate T, Ban N, Hirata Y, Hashida H, Saito K, Iwashiro N, Ohara M, Ishizaka M, Azumad M, Hayashi T, Takayama T: Two cases of inverted hyperplastic polyps of the colon and association with adenoma. *Eur J Gastroenterol Hepatol* 2004, **16**:107–112.
 27. Fu K, Fujii T, Kuwayama H, Ishikawa T, Ueda Y, Fujimori T: Invasive cancer arising in a colonic inverted hyperplastic polyp. *Endoscopy* 2010, **42**:29–30.
 28. Choi HH, Bae SH, Jang EC, Kim SY, Yeom JO, Lee SY, Chang ED, Cho YS: Intramucosal colon cancer developing in an inverted hyperplastic polyp. *Gut Liver* 2013, **7**:126–127.

doi:10.1186/1746-1596-8-187

Cite this article as: Okamoto *et al.*: Overexpression of regenerating gene *la* appears to reflect aberration of crypt cell compartmentalization in sessile serrated adenoma/polyps of the colon. *Diagnostic Pathology* 2013 **8**:187.

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

